Advertisement

Lung Cancer Chemotherapy for Radiation Oncologists

  • Suresh Ramalingam
  • Chandra P. Belani
Part of the Medical Radiology Radiation Oncology book series (MEDRAD)

Keywords

Lung Cancer Clin Oncol Small Cell Lung Cancer Advanced NSCLC Epidermal Growth Factor Receptor Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agra Y, Pelayo M, Sacristan M, Sacristan A, Serra C, Bonfill X (2003) Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev CD001990Google Scholar
  2. Aisner J (1996) Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat. J Clin Oncol 14:658–665PubMedGoogle Scholar
  3. Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1990) Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 8:1563–1574PubMedGoogle Scholar
  4. Alberola V, Camps C, Provencio M, Isla D, Rosell R, Vadell C et al (2003) Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21:3207–3213CrossRefPubMedGoogle Scholar
  5. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P et al (1997) Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15:2090–2096PubMedGoogle Scholar
  6. Belani CP, Natale RB, Lee JS et al (1998) Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17:455aGoogle Scholar
  7. Boni C, Cocconi G, Bisagni G, Ceci G, Peracchia G (1989) Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trial. Cancer 63:638–642PubMedGoogle Scholar
  8. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E et al (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623–631PubMedGoogle Scholar
  9. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B et al (1989) Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602–1613PubMedGoogle Scholar
  10. Bunn PA Jr (2002) Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 20:23S–33SPubMedGoogle Scholar
  11. Bunn PA Jr, Shepherd FA, Sandler A, Le Chevalier T, Belani CP, Kosmidis PA et al (2003) Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer 41[Suppl 1]:S175–S186CrossRefPubMedGoogle Scholar
  12. Byrne A, Carney DN (1994) Small cell lung cancer in the elderly. Semin Oncol 21:43–48Google Scholar
  13. Chiappori AA, Rocha-Lima CM (2003) New agents in the treatment of small-cell lung cancer: focus on gemcitabine. Clin Lung Cancer 4[Suppl 2]:S56–S63PubMedGoogle Scholar
  14. Dautzenberg B, Chastang C, Arriagada R, Le Chevalier T, Belpomme D, Hurdebourcq M et al (1995) Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients. GETCB (Groupe d'Etude et de Traitement des Cancers Bronchiques). Cancer 76:779–786PubMedGoogle Scholar
  15. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B et al (2002) Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20:247–253CrossRefPubMedGoogle Scholar
  16. Einhorn LH, Pennington K, McClean J (1990) Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. Semin Oncol 17:32–35PubMedGoogle Scholar
  17. Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66–72Google Scholar
  18. Ellis PA, Talbot DC, Priest K, Jones AL, Smith IE (1995) Dose intensification of carboplatin and etoposide as first-line combination chemotherapy in small cell lung cancer. Eur J Cancer 31A:1888–1889PubMedGoogle Scholar
  19. Ettinger DS, Lagakos S (1982) Phase III study of CCNU, cyclophosphamide, adriamycin, vincristine, and VP-16 in small-cell carcinoma of the lung. Cancer 49:1544–1554PubMedGoogle Scholar
  20. Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G (1985) VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 3:1471–1477PubMedGoogle Scholar
  21. Feld R, Rubinstein L, Thomas PA (1993) Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group. J Natl Cancer Inst 85:299–306PubMedGoogle Scholar
  22. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354–2362PubMedGoogle Scholar
  23. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E et al (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016–3024PubMedGoogle Scholar
  24. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T et al (1991) Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83:855–861PubMedGoogle Scholar
  25. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237–2246CrossRefPubMedGoogle Scholar
  26. Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K et al (1998) Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. J Clin Oncol 16:2126–2132PubMedGoogle Scholar
  27. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G et al (1993) Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 11:873–878PubMedGoogle Scholar
  28. Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, DeMarinis F et al (2000) Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 18:3390–3399PubMedGoogle Scholar
  29. Georgoulias V, Pallis AG, Kourousis C, Alexopoulos A, Ardavanis A, Agelidou A et al (2003) Docetaxel versus docetaxel/cisplatin in patients with advanced non-small-cell lung cancer: preliminary analysis of a multicenter, randomized phase III study. Clin Lung Cancer 4:288–293PubMedGoogle Scholar
  30. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M et al (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357:1478–1484CrossRefPubMedGoogle Scholar
  31. Giaccone G, Dalesio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JT et al (1993) Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 11:1230–1240PubMedGoogle Scholar
  32. Gralla RJ, Casper ES, Kelsen DP, Braun DW Jr, Dukeman ME, Martini N et al (1981) Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 95:414–420PubMedGoogle Scholar
  33. Green RA, Humphrey E, Close H, Patno ME (1969) Alkylating agents in bronchogenic carcinoma. Am J Med 46:516–525CrossRefPubMedGoogle Scholar
  34. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F et al (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362–372PubMedGoogle Scholar
  35. Gridelli C, Shepherd FA, Perrone F, Illiano A (2002) Gemvin III: a phase III study of gemcitabine plus vinorelbine (GV) compared to cisplatin plus vinorelbine or gemcitabine chemotherapy (PCT) for stage IIIb or IV non-small cell lung cancer (NSCLC): an Italo-Canadian study. Proc Am Soc Clin Oncol 21:292 (abstract 1165)Google Scholar
  36. Hanna NH, Einhorn LH (2002) Small-cell lung cancer: state of the art. Clin Lung Cancer 4:87–94PubMedGoogle Scholar
  37. Hanna NH, Shepherd FA, Rosell R, Pereira JR, DeMarinis F, Fossella F (2003) A phase III study of pemetrexed vs docetaxel in patietns with recurrent non-small cell lung cancer who were previously treated with chemotherapy. Proc Am Soc Clin Oncol 22:622Google Scholar
  38. Harpole DH Jr, Herndon JE 2nd, Young WG Jr, Wolfe WG, Sabiston DC Jr (1995) Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 76:787–796PubMedGoogle Scholar
  39. Herbst RS, Giaccone G, Schiller J, Miller V, Natale R, Rennie P et al (2003) Subset analyses of INTACT results for gefitinib(ZD1839) when combined with platinum-based chemotherapy for advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 22:627Google Scholar
  40. Hong WK, Nicaise C, Lawson R, Maroun JA, Comis R, Speer J et al (1989) Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group. J Clin Oncol 7:450–456PubMedGoogle Scholar
  41. Iaffaioli RV, Tortoriello A, Gravina A, Facchini G, Turitto G, Elia S et al (2000) Phase I-II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB-IV non-small cell lung cancer. Lung Cancer 30:203–210CrossRefPubMedGoogle Scholar
  42. Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF et al (1994) Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 12:2022–2034PubMedGoogle Scholar
  43. Isla D, Rosell R, Sanchez JJ, Carrato A, Felip E, Camps C et al (2001) Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 19:1071–1077PubMedGoogle Scholar
  44. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics, 2003. CA Cancer J Clin 53:5–26PubMedGoogle Scholar
  45. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S et al (2003) Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 9:5880–5887PubMedGoogle Scholar
  46. Johnson DH, Einhorn LH, Birch R, Vollmer R, Perez C, Krauss S et al (1987) A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 5:1731–1738PubMedGoogle Scholar
  47. Kakolyris S, Papadakis E, Tsiafaki X, Kalofonos C, Rapti A, Toubis M et al (2001) Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study. Lung Cancer 32:179–187CrossRefPubMedGoogle Scholar
  48. Katakami N, Takada M, Negoro S, Ota K, Fujita J, Furuse K et al (1996) Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan. Cancer 77:63–70CrossRefPubMedGoogle Scholar
  49. Kato H, Tsuboi M, Ohta M, Hata E, Tsubota N (2003) A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I adenocarcinoma of the lung. Proc Am Soc Clin Oncol 22:621Google Scholar
  50. Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ et al (2000) A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 343:1217–1222CrossRefPubMedGoogle Scholar
  51. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM et al (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19:3210–3218PubMedGoogle Scholar
  52. Kelly K (2001) Treatment of extensive stage small cell lung cancer. Cancer Treat Res 105:253–276PubMedGoogle Scholar
  53. Klastersky J, Sculier JP, Ravez P, Libert P, Michel J, Vandermoten G et al (1986) A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 4:1780–1786PubMedGoogle Scholar
  54. Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P et al (1990) A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 8:1556–1562PubMedGoogle Scholar
  55. Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J et al (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20:3578–3585CrossRefPubMedGoogle Scholar
  56. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158CrossRefPubMedGoogle Scholar
  57. Langer C, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D et al (2002) Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173–181PubMedGoogle Scholar
  58. Langer C, Vangel M, Schiller J, Harrington D, Sandler A, Belani CP et al (2003a) Age-specific subanalysis of ECOG 1594: Fit elderly patients (70–80 yrs) with NSCL do as well as younger pts (>70 years). Proc Am Soc Clin Oncol 22:639Google Scholar
  59. Langer C, Stephenson P, Schiller J, Tester WJ, Rapoport BL (2003b) ECOG 1599: Randomized phase II study of paclitaxel/carboplatin vs cisplatin/gemcitabine in performance status (PS) w patients with treatment-naive advanced NSCLC. Lung Cancer 41:S18CrossRefGoogle Scholar
  60. Lassen U, Kristjansen PE, Osterlind K, Bergman B, Sigsgaard TC, Hirsch FR et al (1996) Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann Oncol 7:365–371PubMedGoogle Scholar
  61. Lebeau B, Chastang C, Allard P, Migueres J, Boita F, Fichet D (1992) Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. The “Petites Cellules” Group. Eur Respir J 5:286–290PubMedGoogle Scholar
  62. LeChevalier T (2003) Results of the randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy vs no chemotherapy in 1867 patients with resected non-small cell lung cancer. Proc Am Soc Clin Oncol 22:2 (abstract 6)Google Scholar
  63. Lilenbaum RC, Herndon JE 2nd, List M, Desch C, Watson D, Holland J et al (2002) Single agent versus combination chemotherapy in patients with advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life and cost-effectiveness. Proc Am Soc Clin Oncol 21:1aGoogle Scholar
  64. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S et al (1992) CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225–1229PubMedGoogle Scholar
  65. Maurer LH, Tulloh M, Weiss RB, Blom J, Leone L, Glidewell O et al (1980) A randomized combined modality trial in small cell carcinoma of the lung: comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactiv whole brain irradiation. Cancer 45:30–39PubMedGoogle Scholar
  66. Messeih AA, Schweitzer JM, Lipton A, Harvey HA, Simmonds MA, Stryker JA et al (1987) Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer. Cancer Treat Rep 71:61–66PubMedGoogle Scholar
  67. Miller VA, Patel J, Shah NT, Kris M, Tyson L, Pizzo B (2003) The epidermal growht factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma: Preliminary results of a phase II trial. Proc Am Soc Clin Oncol 22:619Google Scholar
  68. Mountain CF, Dresler CM (1997) Regional lymph node classification for lung cancer staging. Chest 111:1718–1723Google Scholar
  69. Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A et al (1999) Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17:2300–2308PubMedGoogle Scholar
  70. Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N et al (2003) Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 88:335–341CrossRefPubMedGoogle Scholar
  71. Niho S, Nagao K, Nishiwaki Y, Yokoyama A (1999) Randomized multicenter phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting, abstract 1897Google Scholar
  72. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85–91CrossRefPubMedGoogle Scholar
  73. Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899–909Google Scholar
  74. Osterlind K, Ihde DC, Ettinger DS, Gralla RJ, Karrer K, Krauss S et al (1983) Staging and prognostic factors in small cell carcinoma of the lung. Cancer Treat Rep 67:3–9PubMedGoogle Scholar
  75. Pantel K, Izbicki JR, Angstwurm M, Braun S, Passlick B, Karg O et al (1993) Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res 53:1027–1031PubMedGoogle Scholar
  76. Passlick B, Kubuschok B, Izbicki JR, Thetter O, Pantel K (1999) Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer. Ann Thorac Surg 68:2053–2058CrossRefPubMedGoogle Scholar
  77. Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L et al (2001) A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:310aGoogle Scholar
  78. Pfeiffer P, Sorensen P, Rose C (1995) Is carboplatin and oral etoposide an effective and feasible regimen in patients with small cell lung cancer? Eur J Cancer 31A:64–69CrossRefPubMedGoogle Scholar
  79. Pisters KM, Ginsberg RJ, Giroux DJ, Putnam JB, Jr., Kris MG, Johnson DH et al (2000) Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 119:429–439CrossRefPubMedGoogle Scholar
  80. Pujol JL, Douillard JY, Riviere A, Quoix E, Lagrange JL, Berthaud P et al (1997) Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J Clin Oncol 15:2082–2089PubMedGoogle Scholar
  81. Ramalingam S, Belani CP (2003) Results of clinical trials for locally advanced and metastatic nonsmall-cell lung cancer. Semin Thorac Cardiovasc Surg 15:438–447CrossRefPubMedGoogle Scholar
  82. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK et al (1988) Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer — report of a Canadian multicenter randomized trial. J Clin Oncol 6:633–641PubMedGoogle Scholar
  83. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A et al (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330:153–158PubMedGoogle Scholar
  84. Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R et al (2002) Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 13:1539–1549CrossRefPubMedGoogle Scholar
  85. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ et al (1992) Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282–291PubMedGoogle Scholar
  86. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS et al (1994) A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86:673–680PubMedGoogle Scholar
  87. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA et al (1986) A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 4:14–22PubMedGoogle Scholar
  88. Rudd RM, Gower NH, James LE et al (2002) Phase III randomised comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:292aGoogle Scholar
  89. Rudin CM, Kosloff M, Edelman MJ, Hoffman PC (2003) Phase I study of G3139 (oblimersen sodium), carboplatin, and etoposide in previously untreated extensive stage small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 22:631 (abstract 2538)Google Scholar
  90. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122–130PubMedGoogle Scholar
  91. Scagliotti GV, Fossati R, Torri V, Crino L, Giaccone G, Silvano G et al (2003) Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 95:1453–1461PubMedGoogle Scholar
  92. Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr (1979) cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63:1459–1473PubMedGoogle Scholar
  93. Schiller JH, Adak S, Cella D, DeVore RF 3rd, Johnson DH (2001) Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19:2114–2122PubMedGoogle Scholar
  94. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98CrossRefPubMedGoogle Scholar
  95. Sederholm C (2002) Gemcitabine compared with gemcitabine plus carboplatin in advanced non-small cell lung cancer: a phase III study by the Swedish Lung Cancer Study Group. Proc Am Soc Clin Oncol 21:291aGoogle Scholar
  96. Shah NT, Miller VA, kris MG, Patel J, Venkatraman ES, Benporat L (2003) Broncioalveolar histoloty and smoking history predict response to gefitinib. Proc Am Soc Clin Oncol 22:628Google Scholar
  97. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–2103PubMedGoogle Scholar
  98. Shihabi S, Belani CP (2001) Role of topoisomerase I inhibitors in small-cell lung cancer. Clin Lung Cancer 2:275–281PubMedGoogle Scholar
  99. Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P et al (1994) Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 5:601–607PubMedGoogle Scholar
  100. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F et al (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21:3909–3917CrossRefPubMedGoogle Scholar
  101. Smith IE, O'Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF et al (2001) Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19:1336–1343PubMedGoogle Scholar
  102. Smythe WR (2001) Treatment of stage I and II non-small-cell lung cancer. Cancer Control 8:318–325PubMedGoogle Scholar
  103. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R et al (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20:1335–1343PubMedGoogle Scholar
  104. Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG et al (1989) Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 59:578–583PubMedGoogle Scholar
  105. Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C et al (2001) Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 92:2639–2647CrossRefPubMedGoogle Scholar
  106. Thatcher N, Eckardt J, Green M (2003) Options for first-and second-line therapy in small cell lung cancer-a workshop discussion. Lung Cancer 41[Suppl 4]:S37–S41CrossRefPubMedGoogle Scholar
  107. Treat J, Belani CP, Edelman MA, Socinski MA, Gonin R, Ansari RH et al (2003) A randomized phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel vs paclitaxel plus carboplatin in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 22:624Google Scholar
  108. Von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658–667PubMedGoogle Scholar
  109. Von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P et al (2000) Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 18:1351–1359PubMedGoogle Scholar
  110. Wada H, Hitomi S, Teramatsu T (1996) Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol 14:1048–1054PubMedGoogle Scholar
  111. Wada H, Miyahara R, Tanaka F, Hitomi S (1999) Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). Eur J Cardiothorac Surg 15:438–443CrossRefPubMedGoogle Scholar
  112. West J (2003) Gefitinib for the treatment of bronchioloalveolar carcinoma-Prelimary results of a South West Oncology Group (SWOG) Trial, 4th Internation Lung Cancer Congress, Maui, HIGoogle Scholar
  113. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH et al (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16:2459–2465PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Suresh Ramalingam
    • 1
  • Chandra P. Belani
    • 2
    • 3
  1. 1.University of Pittsburgh School of MedicinePittsburghUSA
  2. 2.University of Pittsburgh School of MedicineUSA
  3. 3.Lung & Thoracic Cancer ProgramUniversity of Pittsburgh Cancer InstitutePittsburghUSA

Personalised recommendations